Otolaryngology–Head and Neck Surgery Outcomes
Sleep Medicine and Surgery
Mass Eye and Ear is a world-leader in implanting the only FDA-approved hypoglossal nerve stimulation device, which is manufactured by Inspire Medical Systems©. The hospital performs the most implantations in New England and was recognized by Inspire Medical Systems in 2021 as one of nine programs with a “Physician of Excellence.”
Hypoglossal nerve stimulator implantation for obstructive sleep apnea
Since launching its hypoglossal nerve stimulation program in 2019, the Sleep Surgery team at Mass Eye and Ear has implanted more than 300 hypoglossal nerve stimulators (HGNS) in adults with obstructive sleep apnea.
This analysis includes all HGNS patients who have completed the four-month, post-implantation sleep study as of April 2022 (n=128). The primary outcome measure is the apnea-hypopnea index (AHI), which is reported during the optimal setting of an in-lab titration polysomnography, or the entire-night AHI on a home sleep apnea test. This metric demonstrates a mean improvement from severe obstructive sleep apnea to low-mild.
Similar to continuous positive pressure airway therapy, effectiveness of HGNS therapy depends on both efficacy and adherence to therapy1. Objective compliance of all patients is a mean of seven hours of use per night and 80 percent of nights with more than four hours of use.
Apnea-hypopnea index scores before and after implantation
- Huyett P. Early objective adherence to hypoglossal nerve stimulation therapy. J Clin Sleep Med. 2022 Feb 1; 18(2): 631-636.